0001437749-22-028610.txt : 20221207 0001437749-22-028610.hdr.sgml : 20221207 20221207084537 ACCESSION NUMBER: 0001437749-22-028610 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20221207 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20221207 DATE AS OF CHANGE: 20221207 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Moleculin Biotech, Inc. CENTRAL INDEX KEY: 0001659617 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 474671999 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37758 FILM NUMBER: 221449202 BUSINESS ADDRESS: STREET 1: 5300 MEMORIAL DRIVE STREET 2: SUITE 950 CITY: HOUSTON STATE: TX ZIP: 77007 BUSINESS PHONE: 713-300-5160 MAIL ADDRESS: STREET 1: 5300 MEMORIAL DRIVE STREET 2: SUITE 950 CITY: HOUSTON STATE: TX ZIP: 77007 8-K 1 mbrx20221206_8k.htm FORM 8-K mbrx20221206_8k.htm
false 0001659617 0001659617 2022-12-07 2022-12-07
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
 
PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
 
DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): December 7, 2022
 
logo.jpg
 
MOLECULIN BIOTECH, INC.
(Exact Name of Registrant as Specified in its Charter)
 
Delaware
001-37758
47-4671997
(State or Other Jurisdiction of
Incorporation or Organization)
(Commission File No.)
(I.R.S. Employer Identification
No.)
 
5300 Memorial Drive, Suite 950, Houston, TX 77007
(Address of principal executive offices and zip code)
 
(713) 300-5160
(Registrant’s telephone number, including area code)
(Former name or former address, if changed from last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-14(c))
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).          Emerging growth company 
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
Trading Symbol (s)
Name of each exchange on which registered
Common Stock, par value $.001 per share
MBRX
The NASDAQ Stock Market LLC
 
 
 

 
 
Item 7.01
Regulation FD Disclosure
 
On December 7, 2022, Moleculin Biotech, Inc. (the “Company”), issued a press release announcing that the U.S. Food and Drug Administration (“FDA”) has granted Fast Track designation of WP1122 for the treatment of Glioblastoma Multiforme (“GBM”). 
 
A copy of the press release is attached to this report as Exhibit 99.1 and is incorporated by reference herein.
 
The information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be “filed” for the purpose of the Securities Exchange Act of 1934, as amended (“Exchange Act”), nor shall it be incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended (“Securities Act”), unless specifically identified therein as being incorporated by reference.
 
Item 9.01
Financial Statements and Exhibits.
 
(d)
Exhibits.
 
Exhibit No.
Description
 
99.1
 
104
Cover page Interactive Data File (formatted as Inline XBRL document)
 
 
 
SIGNATURE
 
Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
MOLECULIN BIOTECH, INC. 
 
       
       
 
Date:
December 7, 2022
 
       
 
By:
/s/ Jonathan P. Foster
 
   
Jonathan P. Foster
 
 
 
 
EX-99.1 2 ex_453744.htm EXHIBIT 99.1 ex_453744.htm

Exhibit 99.1

 

logo.jpg

Moleculin Granted FDA Fast Track Designation of WP1122 for the Treatment of Glioblastoma Multiforme

 

HOUSTON, December 7, 2022 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that the U.S. Food and Drug Administration (“FDA”) has granted Fast Track designation of WP1122 for the treatment of Glioblastoma Multiforme (“GBM”). The FDA's Fast Track designation is intended to potentially facilitate the development and expedite the review of novel therapies to treat serious conditions for which there is unmet medical need. With the Fast Track designation, Moleculin is potentially eligible for more frequent regulatory meetings and communications with the FDA.

 

“We believe receiving Fast Track designation validates the serious unmet medical need for the treatment of GBM, the most aggressive form of malignant primary brain cancer,” commented Walter Klemp, Chairman and Chief Executive Officer of Moleculin. “We believe that based on the promising animal model data that supports GBM as one of many potential indications, the clearance of our IND for WP1122 in GBM, and Orphan Drug Designation previously received from the FDA, WP1122 is well-positioned to be a potential treatment option for this devastating disease.”

 

GBM is the most aggressive malignant primary brain tumor and remains as an incurable tumor with a median survival of only 15 months.1 It is the most common malignant primary brain tumor making up 54% of all gliomas and 16% of all primary brain tumors,2 and despite advancements, survival rates for patients with GBM have shown no notable improvement in population statistics in the last three decades.3 The average annual age-adjusted incidence rate of GBM is 3.19 per 100,000 persons in the United States.4

 

WP1122 was developed as a 2-DG prodrug to provide a more favorable pharmacological profile and was found to have greater potency than 2-DG alone in preclinical models where tumor cells require higher glycolytic activity than normal cells. Although activity in animals does not necessarily translate to humans, preclinical studies in mice transplanted with human brain tumors showed that WP1122 outperformed the standard of care, temozolomide, and performed even better in combination with temozolomide.

 

In September of 2022, Moleculin was granted Orphan Drug Designation of WP1122 for the treatment of GBM from the FDA. Additionally, based on preclinical data indicating the potential for WP1122 as a treatment for GBM, Moleculin received FDA clearance of its Investigational New Drug application to initiate a Phase 1 open label, single arm, dose escalation study of the safety, pharmacokinetics and efficacy of oral WP1122 in adult patients with GBM. The Company is currently evaluating opportunities for collaboration in clinical development.

 

About Moleculin Biotech, Inc.

 

Moleculin Biotech, Inc. is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of highly resistant tumors and viruses. The Company’s lead program, Annamycin is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity. Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases.

 

 

 

Additionally, the Company is developing WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers, and WP1220, an analog to WP1066, for the topical treatment of cutaneous T-cell lymphoma. Moleculin is also engaged in the development of a portfolio of antimetabolites, including WP1122 for the potential treatment of COVID-19 and other viruses, as well as cancer indications including brain tumors, pancreatic and other cancers.

 

For more information about the Company, please visit www.moleculin.com and connect on Twitter, LinkedIn and Facebook.

 

Forward-Looking Statements

 

Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the Company’s ability to establish a suitable collaboration for the development of WP1122 for the treatment of brain tumors, the ability for WP1122 to be shown to be effective in a human clinical trial for brain tumors, and the ability for WP1122 to reviewed and approved by the FDA. Although Moleculin believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Moleculin has attempted to identify forward-looking statements by terminology including ‘believes,’ ‘estimates,’ ‘anticipates,’ ‘expects,’ ‘plans,’ ‘projects,’ ‘intends,’ ‘potential,’ ‘may,’ ‘could,’ ‘might,’ ‘will,’ ‘should,’ ‘approximately’ or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under Item 1A. “Risk Factors” in our most recently filed Form 10-K filed with the Securities and Exchange Commission (“SEC”) and updated from time to time in our Form 10-Q filings and in our other public filings with the SEC. Any forward-looking statements contained in this release speak only as of its date. We undertake no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.

 

Investor Contact:

 

JTC Team, LLC

Jenene Thomas

(833) 475-8247

MBRX@jtcir.com

 

1: Koshy M, Villano JL, Dolecek TA, Howard A, Mahmood U, Chmura SJ, et al. Improved survival time trends of glioblastoma using the SEER 17 population-based registries. J Neuro Oncol. 2012;107(1):207-12

2: Ostrom QT, Gittleman H, Farah P, Ondracek A, Chen Y, Wolinsky Y, et al. CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2006-2010. Neuro Oncol. 2013;15 Suppl:2ii-56.

3: De Vleeschouwer S, editor. Brisbane (AU): Codon Publications; 2017 Sep 27.

4: Thakkar J, Dolecek TA, Horbinski C, Ostrom QT, Lightner DD, Barnholtz-Sloan JS, et al. Epidemiologic and molecular prognostic review of glioblastoma. Cancer Epidemiol. Biomarkers Rev. 2014;23(10):1985-96.

 

 
EX-101.SCH 3 mbrx-20221207.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink EX-101.DEF 4 mbrx-20221207_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 5 mbrx-20221207_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity [Domain] Legal Entity [Axis] Document Information [Line Items] Document Information [Table] Document, Type Document, Period End Date Entity, Registrant Name Entity, Incorporation, State or Country Code Entity, File Number Entity, Tax Identification Number Entity, Address, Address Line One Entity, Address, City or Town Entity, Address, State or Province Entity, Address, Postal Zip Code City Area Code Local Phone Number Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Entity, Emerging Growth Company Title of 12(b) Security Trading Symbol Security Exchange Name Amendment Flag Entity, Central Index Key EX-101.PRE 6 mbrx-20221207_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 7 logo.jpg begin 644 logo.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_X0 L17AI9@ 34T *@ @ 0$Q ( M * &@ !''EZ@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3% MQL?(R;GZ.GJ\?+S]/7V]_CY^O_$ !\! ,! 0$! M 0$! 0$ ! @,$!08'" D*"__$ +41 (! @0$ P0'!00$ $"=P ! M @,1! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D: M)BH*# MA(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3 MU-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_: P# 0 "$0,1 #\ ^D:*** " MNV@X_^N*Z.N7UOP8U]K@UK1-4ET;4 M6B\J:6&)76=>V]3P2/6NK#*@YM5W96T]?/1_D5&U]3HK2[M[^SBNK*9)X)E# MQR(]35YMX'UC3_!<-YX7\27T=I?6UPT@EFDQ'.C\AESPO'45U6N7VH6[ MV&HZ7<))IN3]J"QB0%",J^1S@'J1G@YP<5.)H^QJ.*U71]UT9URP<_:\BV>S M>STNK>O3S-^BJ>E:G;ZQIL5[9N'BD'&#G!!P1^=7*Y[W.2490DXR5F@HHHH) M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ J"^O(]/T^XO)PQBMXFE<*,G"C)Q^53U6U&R34M+NK*1F1+F%HF M9>H##&?UJH%1)X;AW;V:4>>RCJXYZ#!SP?K7 MH>@:W;>(]!M=6L1(L%TFY5D&&&"00?Q!KS!/!GQ"T;39/">CWUC/HEP'47DB MA7A1L[E(Z\Y/3/U%=//=Q?"7X:VD4@DU-H'\E-H";W3QC;K=VFL@36U[-#YH M7!YB(P<8R.W0"K'AGQ.VD^%]=O-.MGN]&L[SR]/5VVG:QY7)'W02,=^:$N?B M0R?VWJ&G6-Q:'KHV 75/[P//S?B?I72VCZ;XX\"7$>EQ_8X;I6C9#$%,4@.3 MD#K@XKS<;S6U:;T5T[K3^O0^MYX1HKVT>:+<5)J5TK>5KIVTNG9ZV'6'B"XT MZRV>(]/CT^7898Q;?-&Z]2!_M 17!3ZIJEU/8>'=0TEGU* M":.1Y8R/)>$?*9 3Z@L,>_X5V6FI<6\+6]W+'*T381E/)C_A+#UZ_E7BTZC< MG'H>9CJ"@E.R3>MD[IKHUOIZLN45%]KM_P#GO%_WV*D#!E!4@@]".]=":>QY MC36XM%1?:K<=9XO^^Q4BLKJ&1@RGH0@G R>!3$%%1?:[?_ )^(O^^Q1]KM_P#GXB_[[%3S1[E?3>*ESCK0FGL#36X45$+F!F"K-&2> XYIS MS1Q8\V1$STW,!FCF6]PY7M8?134D21*1L1RHY]%8&G.ZQKN=@J^I.*+JUPL[V%HIB31 M2DB.1'(ZA6!HH33V!IK]2R>56B MIQG[[CS)=+7M\5[7\CG=9*5K:'ME]J5CID2R:E>06B.VU6GD" GT!-<-\2@G MB[P3+;>&)[?5+FWGCG:&UG5V"C()P#[UR NI?B;\4K+3?&%A+I%I:6S21Z9* M[!IF[\X4\]>W"U?UO1K'X=?$;P]/X1B9#J!-O<:J_6NFC M@(X6K!.3]M;F2LG'2[M>_9;K3S-L/4E*I>/0Z6R^+GAQM#:XO7FMKR'"26+Q MGS=_H.Q'OQCOBL[X;>)+33(9](UB.739[FY>ZMOM2[%='Q@ GOQ7=7'AK1;K M6(]5N--MY+Z,86=DY^I[$^YZ5D_$>QMKKP1?RW$"226Z!XG8I M1:?LHM7[O\CW\+6P\ M5#Y2NS!E^;TX//O70V,UF_BK4A#,CSF.+<%;/&#Q_7\:FTC2K&/PQ;V26D0M MI(%WQ;>&RHSGU/O6=X0T>QBT2RN8X%6:-Y2''4Y8KR>_ %>0XU%4BM'K?]/U M,ZU3#RIRY$URKEZ.^[3?W?EVU\UU^P:T\0ZA!$IV0RLWT4GC^8KO_#FM"/X< M27+-\]E&\?XC[O\ ,5EZA8B^^(FK6@&3-9$#_>\MUT"^TSG%Q( MC?3;G/\ 2ODZ=3ZAB*DUL^=?-;?H?1U*?]H8>G![KD;]'O\ J4&5RGFMG:S$ M9/<_Y->K>']232/AK!?2C<(8W(7^\=Y 'YD5P>K67V/PMHS$8>X,TK?B5 _0 M"NBNE=O@[;[.BL"WT\T_UQ2R[GPU2K);JG?[[,,RY,53I1>SJ6^ZZ.8#ZMXO MUL1F0S32$D G"1C^@%6];\&ZGH%J+R1XY8E(#/$QRA[=?YU>^&;HOB.=7(W- M;,$SW^93_*NX\9.B>$;_ ,P@ Q@#/J2,5MAL!2Q."GB:C;GKK?L98K,*N&QL M,+2BE#16MW,'X?\ B:XU R:9J$AEDC3?%(QR2HZ@GO7'^,O^1PU#_KH/_015 MSX>JS>+X2O18W+?3;C^9%4_&7_(X:A_UT'_H(KGKUIULL@YN]I6_ Z,/0IT< MTFH*UXW_ !/6]#_Y%[3O^O6+_P! %2ZE_P @F[_ZX/\ ^@FHM#_Y%[3O^O6+ M_P! %2ZE_P @F[_ZX/\ ^@FOM8_P%Z?H?#R_WA^OZGANG63ZEJ4%G&X1IY @ M9N@S77_\*PO_ /H(6WY-_A7(:?:S7VI06ULP265PJ,3C!-=;_P (#XB_Y_8O M^_S?X5\'@:,:D&W1<_-.Q]_CJ\J$/#-S]NF241,\Y,>> M1@<<]^*\UN;W5/%NMI&6:269\11!L*@]O3 [UWU_IUUIWPSN+.ZNB^+X0^ 6C<+GUQ_AFO4QR]OJT$X\K!BGE0C7C[(8P-Q SWQTJ+3M;T[5@?[.NXYB!DJ#A@/<'FO5P^7T M,)BDZ52UU\/<\K$9A7Q>%:JT[V?Q6V/%IO\ D.O_ -?)_P#0J]QO/^/&?_KF MW\J\-G^779-W&+DYSV^:OIZ.*PM/$XB$X?'3:OZ?U^IU/PO_ .0M>_\ 7 ?^A"BD^%__ M "%KW_K@/_0J*^IR3_B_(ZWQ7X+T?QE;00ZU%(WV=RT;Q/ MM9!=%\&+PW\VF:A9DA+J 98J>W4=#T M/N?6N7N/#EM\,O,\7:UJ-[XBO(U%O;+/P49L\Y)/;/TR:WKWXP>$;'6ET]KU MYESB2ZA3?#&?0L.OU (J'XH6T_BCX>1R>&T&IJ;B.6-I>SP^)O&E+356T>ZONOO*H*G*JOQ,Y+3XFZH!X@%Y;V,J\P:1_"R'LW; M/U.?<4ZSNO$?Q-MGMYUCT;286\JZ\L[WFD7!*C/0 X_^O5RW^+ND3:6BVEC> MR:L2(ETSRCYF_P"O3'Z^U:W@73;CPUX/E?7O+M9))I+N8%\B(-CJ?H*\W&*: MNJL%'LK6T_7U/IHU:E##NI.E%332AIKUNTNMM+-IZLS+=_%FG72>%C/!,9$+ M0:D?O1PC@Y7^\,@#^M;&A:-/IFKO:#4)IK.S :&-^N9 =P8]\8R/K64OB":Y M\66NNP:7W]I/))O(A<'[@9."5 M_/&?:OGE",ZB=[M/OT_74QQE2K"%I14>9:V2^*]G?L[=-+7>FISEA:7C?%&[ MO)+69+)D/E(6VX M"@=/I6_X=TSSO MOIVHPO'OC=)(W&UAEV_\ UUT-%=,,!3AB)5[_ !*UNEM/ M\CEJ9A4GAH4+?"[WZWU_S/(+_P *:[X?U'SK*.:58VS%<6X)/X@7"J>$\G:N?4\ ?B:]CHKSY9'#6,*DE%]#T8Y]/24Z<7);,Y7P7X4? M089+F]VF\F&W:IR(U],^M<=XKT35+GQ3?36^GW,L;2 JZ1,0>!WKUNBNJME5 M&IAXX>+LHNYRT,VK4L1+$25W)6/'XSXQAB2*)=41$4*JA'P .@KIO"O]NRV6 MK)K"WC9M\1"=6Y.#TS^%=U144,J]C-3]K)VZ/TL7B,V]M!P]E%7ZK?>YXC;Z M-KUIFH_\ @/\ _8UZO16%/(U35H5I+TT. MBIGKJ.\Z,7ZZG,^$3J=_HEW'XC69F>0IMG3:2A4>PXZUQ6K^#]7T/43/ILF<9Q7LE%8U=^"?!UW!J":GJL1@$7,43?>+>I'8"IOB/IM[?W5B;*TFN J.&,49;'(]*[Z MBNC^RZ*PCPL6TGJWU.?^U:SQ:Q4DFUHET/&K.V\5:?"8K*WU*",G<52-P,^M M;GAF3Q0?$EH-2_M#[+N;S/-5MOW3US[XKTFBN>CD_LI1DJLK)[=#HK9S[:,H MNE&[3UZGDOBS1=3N?%5[-;Z?KFDZD:47%?N[?.QYO\ #[2M0L=?EDO+ M*>!# 0&DC*C.1QS4WCSPG--=#4]*MWE:4XGBC7)S_>P/UKT*BDLII?5?JS=U M>]^J*>;UOK?UJ*L[6MT://?ASIE]8:G>->VD\"M" #)&5!.?>BO0J*[,'A8X M2BJ47>QQ8S%2Q=9U9*UPJAKMK+?>'=0M+8!II[:2- 3C+%2!S5^BNV$G"2DN MAQO4\%TK4CHO@>Y\$WG@V\DUZX61%'V=664MG$A;OMR.>1QU%>K?#[1KKP_X M$TW3=101W4*,94# [26)QD>Q%=)@9SCGUJM?:G8Z9&LFI7MO:(QPK3RJ@/TR M:]7%Y@\7%TXPMS/F>K=WY=EY?B94Z7*^YQ&J:EJ.I>.+BR\#V>F+=VD0%_J= MS#G:2>(PPY)Z^OZ52DU?7M8\&>)-(U&!KO5+&=87:UCX>,D'@#KP#[\BH/#^ MEZIJ_B77=8\%ZDNE:/>SA1))")//=?ONBGH,YY]_RZE?LW@G2[/2[-EGO[Z1 MSYLYP99,9>1\M<^-C"'[M=$O7;6_P#D?5TYTZ2C"$5*:Y6M[IKW MGS/MNK+]" 7=UXGTNW_L6TDMK:T 96N5V%Y5&%4#T4G)/J !76VT"6UM'#& MJHH JMHPU :3#_;$B279!+E$V@<\#'TJ]7EPA9\SW9XN*K$_#T>FQ2F9MQDD?HI=NNT= MAZ"MA[>%YTF>&-I8P0DA4%ESUP>U%%95*DJDW.;NV5*I*4G)O5DE%%%00%%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 + %%%% !1110!_]D! end XML 8 R1.htm IDEA: XBRL DOCUMENT v3.22.2.2
Document And Entity Information
Dec. 07, 2022
Document Information [Line Items]  
Entity, Registrant Name MOLECULIN BIOTECH, INC.
Document, Type 8-K
Document, Period End Date Dec. 07, 2022
Entity, Incorporation, State or Country Code DE
Entity, File Number 001-37758
Entity, Tax Identification Number 47-4671997
Entity, Address, Address Line One 5300 Memorial Drive, Suite 950
Entity, Address, City or Town Houston
Entity, Address, State or Province TX
Entity, Address, Postal Zip Code 77007
City Area Code 713
Local Phone Number 300-5160
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity, Emerging Growth Company false
Title of 12(b) Security Common Stock
Trading Symbol MBRX
Security Exchange Name NASDAQ
Amendment Flag false
Entity, Central Index Key 0001659617
XML 9 mbrx20221206_8k_htm.xml IDEA: XBRL DOCUMENT 0001659617 2022-12-07 2022-12-07 false 0001659617 8-K 2022-12-07 MOLECULIN BIOTECH, INC. DE 001-37758 47-4671997 5300 Memorial Drive, Suite 950 Houston TX 77007 713 300-5160 false false false false false Common Stock MBRX NASDAQ EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 1 22 1 false 0 0 false 0 false false R1.htm 000 - Document - Document And Entity Information Sheet http://www.mbrx.com/20221207/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false All Reports Book All Reports mbrx20221206_8k.htm ex_453744.htm mbrx-20221207.xsd mbrx-20221207_def.xml mbrx-20221207_lab.xml mbrx-20221207_pre.xml logo.jpg http://xbrl.sec.gov/dei/2021q4 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "mbrx20221206_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "local": [ "mbrx-20221207_def.xml" ] }, "inline": { "local": [ "mbrx20221206_8k.htm" ] }, "labelLink": { "local": [ "mbrx-20221207_lab.xml" ] }, "presentationLink": { "local": [ "mbrx-20221207_pre.xml" ] }, "schema": { "local": [ "mbrx-20221207.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/currency/2021/currency-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd", "https://xbrl.sec.gov/exch/2021/exch-2021.xsd", "https://xbrl.sec.gov/sic/2021/sic-2021.xsd", "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd" ] } }, "elementCount": 26, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "mbrx", "nsuri": "http://www.mbrx.com/20221207", "report": { "R1": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "mbrx20221206_8k.htm", "contextRef": "d20228K", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000 - Document - Document And Entity Information", "role": "http://www.mbrx.com/20221207/role/statement-document-and-entity-information", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "mbrx20221206_8k.htm", "contextRef": "d20228K", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.mbrx.com/20221207/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.mbrx.com/20221207/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.mbrx.com/20221207/role/statement-document-and-entity-information" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document, Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.mbrx.com/20221207/role/statement-document-and-entity-information" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document, Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.mbrx.com/20221207/role/statement-document-and-entity-information" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity, Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.mbrx.com/20221207/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity, Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.mbrx.com/20221207/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity, Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.mbrx.com/20221207/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity, Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.mbrx.com/20221207/role/statement-document-and-entity-information" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity, Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.mbrx.com/20221207/role/statement-document-and-entity-information" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.mbrx.com/20221207/role/statement-document-and-entity-information" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity, Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.mbrx.com/20221207/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity, File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.mbrx.com/20221207/role/statement-document-and-entity-information" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity, Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.mbrx.com/20221207/role/statement-document-and-entity-information" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity, Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.mbrx.com/20221207/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity, Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.mbrx.com/20221207/role/statement-document-and-entity-information" ], "xbrltype": "employerIdItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.mbrx.com/20221207/role/statement-document-and-entity-information" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.mbrx.com/20221207/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.mbrx.com/20221207/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.mbrx.com/20221207/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.mbrx.com/20221207/role/statement-document-and-entity-information" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.mbrx.com/20221207/role/statement-document-and-entity-information" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.mbrx.com/20221207/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.mbrx.com/20221207/role/statement-document-and-entity-information" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.mbrx.com/20221207/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 16 0001437749-22-028610-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001437749-22-028610-xbrl.zip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end